Track market-moving stories before they get noisy

On February 17, 2026, Parkman Healthcare Partners disclosed a new position in Masimo Corporation (MASI +0.01%), acquiring 200,000 shares in the fourth quarter worth an estimated $26.01 million at quarter’s end.

What happenedAccording to its SEC filing dated February 17, 2026, Parkman Healthcare Partners established a new position in Masimo by buying 200,000 shares. The new stake brought the fund’s quarter-end position in Masimo to $26.01 million.

What else to knowThis was a new position, representing 2.48% of Parkman Healthcare Partners’ $1.05 billion in reportable U.S. equity assets as of December 31, 2025.Top five holdings after the quarter-end filing were:NYSE: BSX: $47.73 million (4.5% of AUM)NASDAQ: PODD: $40.04 million (3.8% of AUM)NASDAQ: DXCM: $38.99 million (3.7% of AUM)NYSE: SYK: $37.07 million (3.5% of AUM)NYSE: CVS: $35.73 million (3.4% of AUM)As of Friday, Masimo shares were priced at $174.69, up about 6% over the past year and well underperforming the S&P 500’s roughly 20% gain in the same period.Company overviewMetricValueMarket Capitalization$9.4 billionRevenue (TTM)$1.5 billionNet Income (TTM)($151.5 million)Price (as of Friday)$175.49Company snapshotMasimo Corporation offers noninvasive patient monitoring technologies, including pulse oximetry, brain function monitoring, capnography, regional oximetry, and hospital automation solutions.The company generates revenue primarily through the sale of proprietary medical devices and software platforms to healthcare providers and OEM partners, leveraging direct sales and distribution channels.It serves hospitals, emergency medical services, home care providers, long-term care facilities, physician offices, veterinarians, and consumers worldwide.Masimo Corporation is a leading provider of advanced noninvasive monitoring technologies and hospital automation solutions, with a global presence in the medical instruments and supplies sector. The company differentiates itself through proprietary signal extraction and multi-parameter monitoring platforms designed to improve patient outcomes and workflow efficiency. Its integrated product suite and established relationships with healthcare institutions underpin its competitive positioning in a rapidly evolving market.

What this transaction means for investorsTakeover premiums can instantly rewrite the investment case for a stock, especially in healthcare where breakthrough technology and strong hospital relationships can command enormous strategic value, and that dynamic is now front and center for Masimo.

Shares have surged 35% this year, the vast majority of which came after the medical technology company announced last month it agreed to be acquired for $180 per share in cash in a transaction valued at roughly $9.9 billion, a deal that would bring the patient monitoring specialist into a major diagnostics platform while allowing it to continue operating as a standalone brand.

The sharp rally this year highlights how quickly sentiment can shift when strategic buyers enter the picture, and it makes this new stake incredibly well timed, especially since shares were otherwise struggling. The transaction is expected to close in the second half of the year. Within the broader portfolio, the new position sits alongside several major healthcare holdings such as Boston Scientific, Dexcom, Insulet, and Stryker. That mix reflects a clear strategy centered on companies that combine strong intellectual property with durable demand from hospitals and chronic disease care.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Insulet and Masimo. The Motley Fool recommends CVS Health and DexCom and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy.

Posted by Defense World Staff on Apr 5th, 2026

SG Americas Securities LLC grew its holdings in shares of Masimo Corporation (NASDAQ:MASI – Free Report) by 84.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,429 shares of the medical equipment provider’s stock after buying an additional 7,510 shares during the period. SG Americas Securities LLC’s holdings in Masimo were worth $2,137,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Viking Global Investors LP purchased a new position in Masimo during the 2nd quarter valued at about $129,096,000. Squarepoint Ops LLC grew its holdings in Masimo by 738.8% in the third quarter. Squarepoint Ops LLC now owns 620,932 shares of the medical equipment provider’s stock worth $91,619,000 after purchasing an additional 546,905 shares during the period. Alyeska Investment Group L.P. increased its stake in shares of Masimo by 21.7% during the third quarter. Alyeska Investment Group L.P. now owns 1,381,085 shares of the medical equipment provider’s stock valued at $203,779,000 after purchasing an additional 246,595 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in shares of Masimo by 20.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,419,250 shares of the medical equipment provider’s stock valued at $209,410,000 after purchasing an additional 238,047 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Masimo by 113.0% during the third quarter. Bank of America Corp DE now owns 405,061 shares of the medical equipment provider’s stock valued at $59,767,000 after purchasing an additional 214,885 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Price Performance Shares of NASDAQ MASI opened at $178.59 on Friday. The firm has a market cap of $9.59 billion, a P/E ratio of -16.94, a PEG ratio of 1.81 and a beta of 1.20. Masimo Corporation has a twelve month low of $125.94 and a twelve month high of $179.00. The company has a quick ratio of 1.47, a current ratio of 2.49 and a debt-to-equity ratio of 0.72. The company has a 50 day moving average of $163.41 and a 200 day moving average of $149.45.

Analysts Set New Price Targets Several analysts recently weighed in on MASI shares. Wells Fargo & Company upgraded Masimo to a “hold” rating in a research note on Wednesday, March 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of Masimo in a research note on Thursday, January 22nd. Stifel Nicolaus set a $180.00 target price on Masimo in a report on Tuesday, February 17th. Piper Sandler downgraded Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price target for the company. in a report on Tuesday, February 17th. Finally, Wolfe Research lowered Masimo from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 19th. Eight analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $181.17.

Check Out Our Latest Stock Analysis on Masimo

About Masimo (Free Report)

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.

Featured Stories Five stocks we like better than Masimo

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEJPMorgan Chase & Co. Has $3.21 Million Stock Position in Vanguard Russell 2000 Growth ETF $VTWG

NEXT HEADLINE »First Majestic Silver Corp. $AG Stake Boosted by SG Americas Securities LLC

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Masimo Corporation (NASDAQ: MASI)'s sale to Danaher Corporation for $180.00 per share in cash. If you are a Masimo shareholder, click here to learn more about your legal rights and options.

CECO Environmental Corp. (NASDAQ: CECO)'s merger with Thermon Group Holdings, Inc. Upon completion of the proposed transaction, CECO shareholders are expected to own approximately 62.5% of the combined company. If you are a CECO shareholder, click here to learn more about your rights and options.

Marine Products Corporation (NYSE: MPX)'s sale to MasterCraft Boat Holdings, Inc. for $2.43 per share in cash and 0.232 shares of MasterCraft common stock for each share of Marine. If you are a Marine shareholder, click here to learn more about your rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Posted by Defense World Staff on Apr 19th, 2026

Sumitomo Mitsui Trust Group Inc. lowered its position in shares of Masimo Corporation (NASDAQ:MASI – Free Report) by 96.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,572 shares of the medical equipment provider’s stock after selling 382,676 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Masimo were worth $1,895,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Jupiter Asset Management Ltd. purchased a new position in Masimo during the third quarter valued at approximately $12,491,000. American Century Companies Inc. grew its stake in Masimo by 10.6% during the third quarter. American Century Companies Inc. now owns 168,341 shares of the medical equipment provider’s stock valued at $24,839,000 after acquiring an additional 16,113 shares in the last quarter. ING Groep NV purchased a new position in Masimo during the third quarter valued at approximately $3,069,000. Citigroup Inc. grew its stake in Masimo by 133.5% during the third quarter. Citigroup Inc. now owns 116,672 shares of the medical equipment provider’s stock valued at $17,215,000 after acquiring an additional 66,710 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in Masimo by 6.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,619,960 shares of the medical equipment provider’s stock valued at $386,575,000 after acquiring an additional 149,567 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Wall Street Analysts Forecast Growth Several equities analysts recently commented on MASI shares. BTIG Research cut shares of Masimo from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 18th. Wells Fargo & Company raised shares of Masimo to a “hold” rating in a research note on Wednesday, March 18th. Stifel Nicolaus set a $180.00 price target on shares of Masimo in a research note on Tuesday, February 17th. Wolfe Research cut shares of Masimo from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. Finally, Raymond James Financial cut shares of Masimo from an “outperform” rating to a “market perform” rating in a research note on Friday, March 27th. Eight investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $181.17.

Check Out Our Latest Research Report on Masimo

Masimo Price Performance MASI stock opened at $178.39 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.49 and a quick ratio of 1.47. Masimo Corporation has a one year low of $125.94 and a one year high of $179.00. The stock has a market cap of $9.58 billion, a PE ratio of -16.93, a P/E/G ratio of 1.81 and a beta of 1.20. The firm has a 50 day simple moving average of $171.53 and a two-hundred day simple moving average of $152.00.

About Masimo (Free Report)

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.

Featured Stories Five stocks we like better than Masimo

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINE24,491 Shares in Unum Group $UNM Acquired by Sumitomo Mitsui Trust Group Inc.

NEXT HEADLINE »Sumitomo Mitsui Trust Group Inc. Has $1.68 Million Stock Holdings in iShares iBoxx $ High Yield Corporate Bond ETF $HYG

NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi, Jackson, alongside online publication in the Journal of Pediatrics. As the authors noted, “[W]e found no evidence of clinically meaningful skin tone-related discrepancies, suggesting equitable monitoring performance for this device in this clinical setting.”1

"Importantly, we found no evidence of clinically meaningful skin tone-related discrepancies, suggesting equitable monitoring performance for this device in this clinical setting."

Share These promising results—from an NIH-funded study that exclusively evaluated Masimo SET® in a vulnerable, clinically fragile patient population—add to previously published evidence of its strong performance under the most challenging real-world conditions across all skin tones. The INSPIRE feasibility study, published late last year, showed that SET® pulse oximetry performed accurately on critically ill adult medical ICU patients of all skin tones, without any occult hypoxemic events2—results similar to the newly published NICU findings,1 as well as prior evaluations of Masimo SET®’s accuracy by skin tone.3-6 The results of the full INSPIRE study—involving approximately 500 adult patients—are expected to be published later this year.

As Dr. Siefkes’ team points out, even when conducted prospectively, with real-world patients, past studies of pulse oximetry accuracy by skin tone in newborns have not used quantitative, objective measurements to classify pigmentation, or have other methodological shortcomings and limitations. Some prior studies have found that oxygen saturation measured by noninvasive pulse oximetry (SpO2) can overestimate arterial blood oxygen saturation (SaO2), which can lead to occult hypoxemia. Noting that accurate detection of hypoxemia is especially important in NICU patients, since it drives many care pathway decisions, the NeoPODS researchers thus set out to conduct a prospective accuracy study in this patient population, hospitalized NICU patients, with rigorous technical methodology: tightly paired, time-synchronized SpO2-SaO2 measurements and objectively classified skin pigmentation across a range of gestational ages using the same sensors and monitors for all patients. Their primary outcome was the mean bias between paired, simultaneously measured SpO2 and SaO2 values, and their secondary outcome, understanding how that bias differed by skin tone.

The researchers enrolled patients between July 2022 and July 2025 at two tertiary NICUs at UC Davis and UM Jackson. The patients were hospitalized newborns up to ten days old, of at least 26 weeks gestational age, with an indwelling arterial catheter and at least one clinically indicated arterial blood draw. Masimo RD SET® Neo sensors connected to Radical-7® Pulse CO-Oximeters® and Root® monitoring platforms were used to continuously record SpO2 data before, during, and after arterial blood gas (ABG) sampling. SaO2 values were directly measured with on-site laboratory analyzers and then paired with the corresponding average SpO2 for the 30 seconds preceding each blood draw. In addition to recording parent-reported race, each patient’s skin tone classification was objectively assessed with a variety of methods, including melanin index and individual typology angle (ITA)—the latter a continuous, quantitative measure of skin pigmentation recommended by the FDA in their 2025 draft guidance for pulse oximeter manufacturers.7 Data was captured by a SkinColorCatch device, and visual scoring was performed by clinicians blinded to each other’s observations using the Massey-Martin and the Fitzpatrick scales.

From among 100 newborns enrolled over the three years, 136 paired SpO2-SaO2 readings collected from 70 patients met the technical criteria for inclusion in the final analysis. The patients’ median gestational age was 28.4 weeks and median gestational weight was 1085 grams (very low birth weight). As identified by their parents, 40% of the patients were Black and 23% were Hispanic. As objectively assessed, their skin pigmentations spanned the full range of ITA classifications and most, but not the darkest, points of the Massey-Martin and Fitzpatrick scales.

The researchers found that overall mean bias between noninvasive SpO2 and invasive SaO2 was -0.98% 2.80% (95% confidence interval, -1.45% to -0.52%), which is not a clinically significant amount, and means that, on average, SpO2 slightly underestimated, not overestimated, SaO2. In fact, there was only one data pair meeting the definition of occult hypoxemia (SaO2<88% when SpO2≥92%), collected from a patient with the lightest ITA skin tone classification; there were zero cases of occult hypoxemia among Black or Hispanic patients.

Turning to accuracy by skin pigmentation, the researchers found that across the objective classification measurements, as well as parent-reported race, there were no statistically or clinically significant differences in mean SpO2-SaO2 bias. For melanin index and ITA classification, when analyzed continuously, bias became slightly less negative with lighter skin pigmentation, but with statistical significance only when ITA analysis was restricted to each patient’s first measurement. There was no significant difference in bias comparing the 3 darkest to the 3 lightest ITA classifications, with all categories except the lightest showing a small negative bias and no statistically significant trend in bias with increasing darkness or lightness. Analyzing bias by Fitzpatrick and Massey-Martin classifications, the researchers similarly found no statistically significant differences (including when analysis was restricted to the first data pair per patient).

The authors concluded that their study is “a novel prospective study of newborns using objective skin pigmentation and closely paired SpO2 and SaO2 measurements assessing pulse oximeter accuracy across skin tones. Our study did not find clinically meaningful pigmentation-related bias. We believe this study provides some reassurance on equitable and accurate care in the NICU for this specific device and population. Our study supports the need for additional age-specific and device-specific pulse oximeter performance assessments.”

Heather Siefkes, M.D., Principal Investigator of the NeoPODS study and Associate Professor at the University of California Davis Children’s Hospital, commented, “In this prospective study of critically ill newborns with tightly paired measurements, we found that pulse oximetry only slightly underestimated arterial oxygen saturation overall and did not demonstrate clinically meaningful differences across skin pigmentation. Bias varied with oxygen saturation, with a tendency toward overestimation at lower SaO2 levels; however, this pattern was not modified by skin pigmentation. Our findings highlight the importance of continued age-, disease-, and device-specific evaluation of pulse oximeter performance.”

Daniel Cantillon, M.D., Chief Medical Officer at Masimo, added, “Concerns about occult hypoxemia in vulnerable neonates, especially with darker skin tones, prompted this large, investigator-initiated and NIH funded real-world study applying rigorous scientific methods. Once again, we’re highly encouraged to see Masimo's RD SET technology demonstrate less than 1% overall bias without occult hypoxemic events among Black or Hispanic infants. This is consistent with the recently published INSPIRE feasibility study results among critically ill adults in the ICU under similarly challenging conditions. However, as the authors note, these findings cannot be extrapolated to other pulse oximeter manufacturers untested on critically ill patients under real-world conditions.”

@Masimo | #Masimo

References

Siefkes H, Holla I, Giusto E, Tancredi D, and Lakshminrusimha S. Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS): A Prospective Study. J Ped. 21 Apr 2026. doi: 10.1016/j.jpeds.2026.115114 Travers A, Terry C, Merrell W, Heincelman M, Warden A, Goodwin A. INSPIRE: Feasibility of a Study Examining the Effect of Skin Pigment on Pulse Oximetry. CHEST Crit Care. 10 Sept 2025. DOI: 10.1016/j.chstcc.2025.100209. Sharma V, Barker S, Sorci R, Park L, Wilson W. Racial effects on Masimo pulse oximetry: impact of low perfusion index. J Clin Monit Comput. 19 Jan 2024. https://doi.org/10.1007/s10877-023-01113-2. Barker SJ, Wilson WC. Racial effects on Masimo pulse oximetry: a laboratory study. J Clin Monit Comput. 2023 Apr;37(2):567-574. https://doi.org/10.1007/s10877-022-00927-w. Foglia EE, Whyte RK, Chaudhary A, Mott A, Chen J, Propert KJ, Schmidt B. The Effect of Skin Pigmentation on the Accuracy of Pulse Oximetry in Infants with Hypoxemia. J Pediatr. 2017 Mar;182:375-377.e2. https://doi.org/10.1016/j.jpeds.2016.11.043. Marlar AI, Knabe BK, Taghikhan Y, Applegate RL, Fleming NW. Performance of pulse oximeters as a function of race compared to skin pigmentation: a single center retrospective study. J Clin Monit Comput. 2025 Feb;39(1):119-125. https://doi.org/10.1007/s10877-024-01211-9. Pulse Oximeters for Medical Purposes – Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations. Draft Guidance for Industry and Food and Drug Administration Staff. January 7, 2025. About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is for our innovations to empower clinicians to transform patient care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2026 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical facts that address activities, events or developments that we expect, believe or anticipate will or may occur in the future. These forward-looking statements include, among others, statements regarding the outcome of future studies evaluating the real-world performance of Masimo SET®; and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “on-going,” “opportunity,” “plan,” “potential,” “predicts,” “forecast,” “project,” “seek,” “should,” “will,” or “would,” the negative versions of these terms and similar expressions or variations, but the absence of such words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: the ability for clinical studies to recruit eligible participants; the ability for the investigator to collect meaningful data; the design of the clinical protocol; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC’s website at www.sec.gov. Forward-looking statements are not guarantees of future performance. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Key Takeaways Masimo study finds less than 1% bias and no skin tone discrepancies in neonatal pulse oximetry accuracy.NeoPODS data shows reliable SpO2 readings with minimal hypoxemia cases across diverse newborn groups.Findings support Masimo's push for equitable monitoring and stronger clinical adoption in NICUs. Masimo recently reported findings from the NeoPODS study, a large prospective real-world evaluation of its SET pulse oximetry technology in critically ill newborns. The study demonstrated less than 1% overall statistical bias and found no clinically significant discrepancies related to skin pigmentation, highlighting consistent accuracy across diverse patient groups.

These findings are significant in the context of longstanding concerns around racial bias in pulse oximetry, where some devices have been shown to overestimate oxygen saturation in patients with darker skin tones. For neonatal intensive care unit (NICU) patients, where precise oxygen monitoring directly influences treatment decisions, such reliability is critical.

Validating Accuracy Across Skin Tones in NICU SettingsThe NeoPODS study enrolled 100 hospitalized newborns across two tertiary NICUs, with 136 paired SpO2-SaO2 measurements from 70 patients meeting strict inclusion criteria. Researchers used rigorous methodology, including tightly paired, time-synchronized measurements and objective skin tone classification techniques such as melanin index and individual typology angle (ITA), aligned with recent FDA guidance.

The findings showed a mean bias of -0.98%, indicating that noninvasive SpO2 measurements slightly underestimated arterial oxygen saturation (SaO2), a clinically favorable outcome. Only one instance of occult hypoxemia was observed, and none occurred among Black or Hispanic patients. Across all skin tone classifications, there were no significant differences in measurement accuracy or bias trends.

MASI Addresses a Critical Gap in Pulse OximetryTraditional pulse oximetry has faced scrutiny due to inconsistent performance across different skin tones. Masimo’s SET technology aims to address these limitations through advanced signal processing designed to improve accuracy under challenging clinical conditions.

The NeoPODS results reinforce earlier findings, including the INSPIRE study in adult ICU patients, which also reported accurate performance across diverse populations. Together, these studies suggest that Masimo’s technology may offer a more reliable alternative in settings where precise oxygen monitoring is essential.

Strategic and Clinical ImplicationsThe study strengthens Masimo’s clinical and regulatory positioning, as healthcare systems and regulators emphasize equitable device performance. Demonstrating accuracy across all skin tones could support broader hospital adoption and reinforce clinician confidence.

From a market perspective, consistent, bias-free monitoring aligns with evolving standards in patient safety and device evaluation. As scrutiny of pulse oximetry intensifies, technologies that reliably serve diverse populations may gain a competitive advantage. Overall, the NeoPODS study reinforces Masimo’s strategy of combining clinical rigor with technological innovation in high-acuity care settings.

MASI’s Peers in Pulse Oximetry SpaceThe pulse oximetry space continues to witness strategic innovation from major MedTech players such as GE HealthCare Technologies Inc. (GEHC - Free Report) , Medtronic plc (MDT - Free Report) and Koninklijke Philips (PHG - Free Report) , each advancing differentiated technologies to enhance accuracy, reliability and equity in oxygen monitoring.

GE HealthCare continues to advance pulse oximetry through its TruSignal SpO2 sensors and interconnect systems designed for continuous, non-invasive monitoring of oxygen saturation and pulse rate. The technology emphasizes accuracy and durability, with high-quality LED components calibrated to device standards and cables engineered to resist wear in clinical environments. TruSignal supports Surgical Pleth Index (SPI) monitoring, expanding its utility in anesthesia care. Performance validation across multiple studies demonstrated strong accuracy under normal, motion and low-perfusion conditions, positioning GE HealthCare’s offering as a reliable solution for diverse clinical settings.

Medtronic continues to strengthen its position in pulse oximetry through the widely adopted Nellcor pulse oximetry, built around OxiMax sensor technology and advanced signal processing. The system embeds calibration data within each sensor, enabling device-independent accuracy, while its heart-centered algorithms enhance performance under motion and low-perfusion conditions. Nellcor offers a broad range of disposable and reusable sensors, including neonatal and pediatric options, alongside bedside monitors and OEM-integrated modules. Clinically, Medtronic’s pulse oximetry system is recognized for strong low-saturation accuracy and reliable performance across diverse patient populations, supporting critical applications from NICU screening to ICU and operating room monitoring.

Philips advances pulse oximetry through its FAST-SpO2 (Fourier Artifact Suppression Technology) algorithm, designed to deliver accurate readings under motion, low perfusion and signal interference. Its approach analyzes signal frequency components to suppress noise and improve reliability in challenging conditions. The company offers a broad sensor portfolio, including Nasal Alar SpO2 Sensors, reusable clips, disposable wraps and ear sensors tailored for neonatal to adult patients. Integrated across IntelliVue monitors and modules, the platform supports continuous monitoring and third-party compatibility. Philips validates its technology against arterial blood gas measurements across diverse populations, reinforcing accuracy and consistency.